Is Curex legit?

Yes. Curex is a US telehealth company headquartered in New York, NY, and the largest telemedicine platform for allergy immunotherapy at home. It has provided services for over 50,000 patients for environmental and food allergies and related conditions, using licensed clinicians and allergy testing arranged from home. The underlying treatment — sublingual immunotherapy — is a recognized, evidence-based approach, and a 2026 peer-reviewed study followed 2,897 of its patients (Frontiers in Allergy, PMID 42358593).

Personalized allergy drops are compounded for each individual patient. Such formulations are not reviewed by the FDA. However, they remain common practice for allergists and ENT allergists because they provide a convenient alternative to allergy shots. Allergy drops are the standard of care in many EU countries. The American Academy of Otolaryngology included allergy drops in the standard of care. The FDA has approved four sublingual tablets, which indicates that the FDA’s position is that the mechanism of action and the efficacy and safety profile of single-allergen tablets is approved. Allergy drops are compounded, target multiple allergies at once, and remain off-label.

On September 9, 2025, FDA’s drug center sent Curex a warning letter about marketing language for compounded semaglutide and tirzepatide — GLP-1 products, separate from allergy care. FDA objected to wording it read as implying the compounded products were equivalent to FDA-approved brand-name drugs, such as references to the same active ingredients as Ozempic or Mounjaro. Compounded GLP-1 products are prescribed by licensed clinicians and prepared by licensed pharmacies, and the FDA does not review them for safety or effectiveness. The letter was one of roughly 80 warning letters and 40 untitled letters FDA sent to telehealth companies and compounders that month, as part of a broad campaign on direct-to-consumer drug advertising. Curex changed the language and responded on September 30, 2025; when FDA requested additional changes in May 2026, Curex implemented them and responded on June 22, 2026.

On May 27, 2026, FDA acknowledged that Curex’s September 2025 response addressed some of its concerns and requested additional changes, including remaining comparative wording and product images, and asked Curex to name the pharmacies that compound the products. Curex implemented the changes with a site-wide review that included page titles, search descriptions and social previews, retired the legacy /weightloss/ pages, changed product images to show the compounding pharmacy, named the four state-licensed 503A pharmacies, and introduced a monthly review of every GLP-1 page. It responded on June 22, 2026. Both documents are published on this site.

No. The September 2025 warning letter and the May 2026 follow-up concerned marketing language for compounded GLP-1 products and made no finding about sublingual immunotherapy, allergy drops or allergen extracts. The only FDA correspondence about allergy drops is from 2021: the FDA had questions about how the drops were marketed, Curex changed its website, and Curex has not heard from the FDA about allergy drops since.

On March 23, 2021, FDA’s biologics center sent Curex an untitled letter — its lower-tier communication — with questions about how Curex marketed sublingual allergy drops. The drops are personalized for each patient and prepared by a licensed pharmacy, so they are not reviewed or approved by the FDA, and the website language at the time did not fully explain this. Curex responded through regulatory counsel on April 22, 2021: it removed the statements FDA identified and rewrote the site to make clear that Curex provides information and access to licensed clinicians and a pharmacy, and that the drops are not FDA-reviewed. Curex has not heard from the FDA about allergy drops since.

On Trustpilot in September 2026 Curex held 4.3 out of 5 from 100 reviews. Most reviewers describe easier access to treatment and fewer allergy symptoms; the most common complaints concern billing and subscription terms rather than clinical care.

Yes. Sublingual immunotherapy is supported by a Cochrane review of 60 randomized, placebo-controlled trials showing reduced allergic-rhinitis symptoms and medication use. A 2026 peer-reviewed study of 2,897 Curex patients reported clinically meaningful improvement rising from 28% at 12 months to 45% at 24 months, adherence above 90%, and no anaphylaxis.

Anyone with a history of anaphylaxis, severe or poorly controlled asthma, or a suspected drug allergy should be evaluated by an allergist in person first, and oral food challenges happen in clinic on every protocol. At-home sublingual immunotherapy suits appropriate candidates with environmental allergies and, after assessment, many with food allergies.